Salarius Pharmaceuticals (NASDAQ:SLRX) Downgraded to Sell Rating by Wall Street Zen

Salarius Pharmaceuticals (NASDAQ:SLRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Salarius Pharmaceuticals Stock Performance

SLRX opened at $0.65 on Friday. Salarius Pharmaceuticals has a one year low of $0.62 and a one year high of $108.00. The stock has a market capitalization of $3.82 million, a P/E ratio of -0.02 and a beta of 0.40. The business’s 50-day simple moving average is $1.36 and its 200-day simple moving average is $5.65.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Friday, November 14th. The company reported ($1.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($33.60) by $31.79.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.